Drug Trial Radar · NCT06720597
EndoPAT Device for Endothelial Dysfunction in ED
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- University of California, IrvineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
Conditions
- Erectile Dysfunction
- Hypogonadism, Male
- Endothelial Dysfunction
Interventions
Daily low-dose PDE5 inhibitor therapyDrug
Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
Testosterone therapy as per clinical guidelines.Drug
Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endothelial Function as Measured by Reactive Hyperemia Index (RHI)Time frame: At baseline, 3 months, and 6 months post-intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCI Urology | Men's Health Center
Newport Beach, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.